Table 2.
Univariate analyses of predictors of overall survival among 86 patients with colorectal cancer liver metastases
| Factor | Univariate analysis | |
|---|---|---|
| Hazard ratio (95% CI) | P‐value | |
| Age, years | ||
| ≥64 | 1.059 (0.605–1.857) | 0.839 |
| <64 | ||
| Gender | ||
| Female | 1.007 (0.532–1.906) | 0.983 |
| Male | ||
| Primary site | ||
| Rectum | 1.304 (0.741–2.349) | 0.347 |
| Colon | ||
| TNM stage | ||
| III, IV | 1.786 (0.895–3.102) | 0.107 |
| I, II | ||
| Timing of operation | ||
| Metachronous | 1.202 (0.644–2.300) | 0.546 |
| Synchronous | ||
| Number of liver metastases | ||
| Multiple | 2.423 (1.387–4.284) | 0.002 |
| Single | ||
| Size of tumor, mm | ||
| ≥50 | 1.873 (0.940–5.327) | 0.069 |
| <50 | ||
| Liver metastasis grade | ||
| B, C | 3.531 (2.166–6.988) | <0.001 |
| A | ||
| Serum CEA, ng/mL | ||
| ≥20 | 1.521 (0.869–2.807) | 0.136 |
| <20 | ||
| Serum CA19‐9, ng/mL | ||
| ≥37 | 1.900 (1.121–3.504) | 0.019 |
| <37 | ||
| DYRK2 expression | ||
| Low | 1.879 (1.088–3.258) | 0.025 |
| High | ||
CA19‐9, carbohydrate antigen 19‐9; CEA, carcinoembryonic antigen; CI, confidence interval; DYRK2, dual‐specificity tyrosine‐regulated kinase 2.